Monoclonal Antibody Therapy: Oncolym

Oncolym (131I Lym-1) is an Iodine 131 radiolabled monoclonal antibody manufactured by Peregrine Pharmaceuticals (formerly Techniclone). It's use is targeted at B-cell non-Hodgkin's lymphoma patients. It is currently in Phase III clinical trials.

How it works:

Oncolym is an antibody with a radioactive substance attached. The drug attaches to a protein found only on the surface of B lymphocytes such as cancerous B-cells found in many forms of Non-Hodgkin's lymphoma. The radioactivity targets the B-cell, destroying it.

The specific B-cell surface marker the antibody attaches to is the HLA-Dr10 protein, a cell surface marker present on over 80% of lymphoma cells. Only about 2% of the normal blood cell population have B-cells that express the HLA-Dr10 marker. This means that Oncolym may selectively target lymphoma cancer cells and may spare healthy B-cells that are responsible for making antibodies that fight infection.


In phase I and II trials, researchers found that 56% of patients that had failed conventional chemotherapy achieved partial or complete remission.

Treatment and Side Effects:

According to the manufacturer, the primary side effect is a decrease in blood cell counts believed to be reversible after treatment ends.

In a small percentage of patients, as with many monoclonal antibodies, the mouse antibodies used are "seen" by the human immune system as foreign, and the human patient mounts an immune response against them, producing HAMA ("human anti-mouse antibodies").





Peregrine Pharmaceuticals, Inc. or

E-mail Form

14282 Franklin Ave., Tustin, CA 92780

Phone: (714) 508-6000 Fax: (714) 838-9433

Links for more information on Oncolym:

Oncolym® information from Peregrine.

New URL: Oncolym information from the NHL Cyber Family


A good account of the Monoclonal Antibody Conference from Judy Gibson


Related Articles

For more information on Adult Non-Hodgkin's Lymphoma, please see the following pages:

Lymphoma Information Network: Monoclonal Antibodies

Lymphoma Information Network: Immunotherapy

Adult Non-Hodgkins Lymphoma: Chemotherapy

Adult Non-Hodgkin's Lymphoma: Treatment

Adult Non-Hodgkin's Lymphoma: Resources

Adult Non-Hodgkin's Lymphoma: Diagnosis

Lymphoma Classification and Types

Adult Non-Hodgkin's Lymphoma: Aggressive NHLs

Adult Non-Hodgkin's Lymphoma: Indolent NHLs

Adult Non-Hodgkin's Lymphoma: Introduction

Other pages you may want to visit:

Lymphoma Information Network

Childhood Non-Hodgkin's Information Pages

More Articles

More Articles is pleased to have the Lymphoma Information Network in the family of associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics


At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...